Snapshot
Enpro Inc. reported $287M of revenue in Q3 2025, up 9.9% year over year, with diluted EPS of $1.01 and an operating margin of 14.3%.
- Revenue
- $287M
- YoY growth
- +9.9%
- Diluted EPS
- $1.01
- Operating margin
- 14.3%
What management said
- •Also, a friendly reminder that we will be making statements on this call, including our perspectives for full year 2025 guidance that are not historical facts and considered forward-looking in nature.
- •Enpro reported organic sales growth of nearly 10% during the third quarter, with mid-single digit revenue growth year-over-year in sealing technologies and more than 17% top line growth at AST.
- •The strength of our business model was demonstrated again during the quarter with total Enpro adjusted EBITDA margin above 24%, which included increased operating expenses supporting both growth initiatives in both segments.
- •Complementing the strong quarterly performance, we continue to advance Enpro 3.0 strategy with the Overlook Industries acquisition and our agreement to acquire Alpha Measurement Solutions, which we announced on October 13th.
- •Both of these acquisitions will expand our capabilities in critical growth areas of the portfolio without the use of excess leverage.
- •Alpha and Overlook are great examples of our ability to identify businesses that fit our strategic growth characteristics while meeting our stringent financial criteria.
- •Overlook's capabilities expand into liquid dose biologics, a secular growth area that continues to expand as liquid single-use medicines are increasingly replacing those taken orally.
- •Our business teams are continuing to identify acquisition targets that broaden our leading-edge capabilities and bring them into Enpro as we strategically expand our portfolio of critical products and solutions.
- •Solid performance in these areas more than offset persistent weakness in commercial vehicle OEM market and soft overall industrial demand in Asia and Europe.
- •In advanced surface technologies segment, sales increased more than 17%, led by growth in leading-edge precision cleaning solutions and improved demand for certain semiconductor tools and assemblies.
- •In sealing technologies, for example, we are currently expanding capacity and investing resources to support future growth in compositional analysis, aerospace, and commercial space applications.
- •Our teams are excited about these efforts as we expand our capabilities and reinvest in growth opportunities to drive long-term profitable growth in sealing technologies.
What went well
- •Enpro reported organic sales growth of nearly 10% in the third quarter, with total sales of $286.6 million, driven by mid-single digit revenue growth in Sealing Technologies and more than 17% top-line growth at AST.
- •Total adjusted EBITDA of $69.3 million increased 8% year-over-year, and adjusted diluted EPS of $1.99 rose more than 14%, helped by operating performance and lower net interest expense.
- •Sealing Technologies sales increased 5.7% to $178.2 million on strength in aerospace, food and biopharma, firm aftermarket demand, and strategic pricing, with segment adjusted EBITDA margin holding above 32% at the high end of the targeted range.
- •AST sales grew 17.3% to $108.5 million, led by leading-edge precision cleaning solutions tied to advanced node chip production for AI and high bandwidth memory, with segment adjusted EBITDA up more than 13%.
- •The company advanced its Enpro 3.0 strategy with the Overlook Industries acquisition (closed October 8) and an agreement to acquire Alpha Measurement Solutions, expanding biopharma single-use technology and compositional analysis capabilities without using excess leverage.
- •The balance sheet remained strong with net leverage at 1.2x trailing-12-month adjusted EBITDA and year-to-date free cash flow of $105 million, up from $83 million a year ago.
What went wrong
- •Total adjusted EBITDA margin of 24.2% was down slightly year-over-year, as ongoing investments in people and processes plus unfavorable mix at AST absorbed the benefits of operating leverage.
- •AST operating leverage was offset by roughly $3 million of growth investments ahead of revenue (accelerated qualification work in Taiwan and the U.S.) and unfavorable mix from increased sales of lower-margin semiconductor tools and assemblies.
- •Sealing faced persistent weakness in the commercial vehicle OEM market and tepid industrial demand in Europe and Asia, while nuclear orders were temporarily impacted by political uncertainty in France affecting funding and procurement.
- •Near-term semiconductor demand remained choppy and is expected to stay so in Q4 and into the first half of 2026, with about $12 million of legacy tools-and-assemblies revenue pulled into 2025 that is not expected to recur in 2026.
Guidance changes
| Metric | Period | Previous | Current | Change |
|---|---|---|---|---|
| Capital expenditures | FY2025 | — | ~$50 million | reaffirmed |
| Net leverage ratio | Year-end 2025 | 1.2x (Q3 actual) | ~2x after announced transactions | increase from deal funding |
| Combined Overlook + Alpha revenue | FY2026 | — | ~$60 million | new |
| Overlook + Alpha Q4 2025 revenue contribution | Q4 2025 | — | just under $10 million revenue, ~$3 million EBITDA | new |
Performance breakdown
| Metric | YoY change | Reason |
|---|---|---|
| Total sales | +~10% (organic) to $286.6M | Strong sealing performance overall and 17%+ AST growth, even with choppy markets |
| Adjusted EBITDA | +8% to $69.3M | Operating performance partly offset by growth investments and AST mix |
| Adjusted EBITDA margin | 24.2%, down slightly | Growth investments in people/processes and unfavorable AST mix absorbed operating leverage |
| Adjusted diluted EPS | +14%+ to $1.99 | EBITDA improvement plus lower net interest expense |
| Sealing Technologies sales | +5.7% to $178.2M | Aerospace, food and biopharma strength, firm aftermarket demand, and strategic pricing offset commercial vehicle OEM weakness |
| AST sales | +17.3% to $108.5M | Acceleration in precision cleaning for advanced node chips plus some recovery in semiconductor tools and assemblies |
| AST adjusted segment EBITDA margin | 20.1% | Operating leverage offset by growth-initiative opex and mix impact of semiconductor tools and assemblies |
| Free cash flow (YTD) | $105M vs $83M | Higher net income and lower interest payments |
Earnings call themes & trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Programmatic M&A (Enpro 3.0) | — | Overlook closed Oct 8 and Alpha agreed Oct 13, both additive to organic growth and accretive to core margins without excess leverage | expanding |
| Compositional analysis / sensing | AMI entry point ~2 years ago with four gas analytes | Alpha adds eight liquid parameters; management sees further M&A opportunity in the space | expanding |
| AST advanced node vs legacy mix | Historically ~50/50 leading edge vs legacy | Now leaning toward advanced node exposure; precision cleaning growing while legacy tools choppy | shifting toward leading edge |
| Semiconductor demand environment | Choppy in recent quarters | Choppy through Q4 and first half 2026, with signals of stronger WFE and capital spending in the back half of 2026 | near-term soft, second-half-2026 recovery expected |
| Supply chain regionalization | Capacity expanded in Southeast Asia over past two years | Demand shifting for certain legacy product lines from U.S. to Asia; ~$12M legacy revenue pulled into 2025 | ongoing |
| Nuclear and commercial space | Big contributors this year; nuclear soft this quarter on France timing | Well-positioned for reactor pressure vessels, SMRs, and space; produced new space parts in nine weeks vs typical 26 | positive long-term |
Q&A summary
What is the relative size, growth, and margin profile of the Overlook and Alpha acquisitions, and what gives Enpro a right to win with Overlook?
Combined ~$60 million of 2026 revenue, growing high single to low double digit, both accretive to Enpro's core with similar profitability. Overlook solves large-molecule liquid biologics processing problems in fill-finish with high recurring revenue from long-lasting customer relationships.
What Q4 revenue contribution from the acquisitions is in guidance?
Just under $10 million of Q4 revenue and approximately $3 million of EBITDA from both acquisitions, depending on Alpha's closing timing (expected by end of November).
When do AST incrementals improve, and what is the $12 million tied to?
Growth investments cost about $3 million in the quarter and should start contributing mid-to-late 2026, with second half of 2026 looking more robust. The $12 million is in tools and assemblies, legacy equipment pulled from 2026 into 2025 to support customers shifting that business from the U.S. to Asia. Historical incrementals for the business are around 40%.
Do the year-one acquisition margins assume integration synergies, and what are long-term margins?
Margins are already healthy; there are few synergies and limited cost-out, so the focus is growth. No Enpro-related margin expansion was contemplated in the first full 2026 year, though continuous improvement and strategic pricing opportunities exist. Long-term margin profile is expected to be about the same as Sealing overall.
What is the AST leading-edge versus legacy mix and the margin difference at maturity?
Historically about 50/50 leading edge versus legacy; now leaning toward advanced node as precision cleaning grows, though stronger legacy tools recently offset that mix. Leading edge carries differentiated, higher margin (new capacity is vertically integrated), and the segment can sustain high-20s to low-30% EBITDA margins over time.
How is the non-French and broader nuclear market positioned, including SMRs versus larger reactors like AP1000?
Enpro is well-positioned in reactor pressure vessels and works with leading companies; it just needs the market to develop. Whether SMR or larger reactor does not significantly matter—SMR seals are smaller but more numerous—so Enpro grows as the industry grows.